BUSINESS PROFILE AND STRUCTURE OF THE GROUP

We develop new technologies, encompassing the entire development path

Business profile

BIOTECHNOLOGICAL CORPORATE GROUP

Biomedycyna Polska S. A. is at the helm of a corporate group of Polish biotechnological companies that specialize in and develop technologies for separation and purification of active pharmaceutical ingredients (API), veterinary medicines as well as dietary supplements. Thanks to holding 100% of the shares of the other group members, the company can offer an integrated business model, starting from development of new technologies, encompassing the entire development path and ending with sale of the product, including proprietary medicinal products.

Biomedycyna Polska S. A. invests into development of innovative pharmaceuticals and APIs for treatment and prevention of the main lifestyle diseases e.g. immune system disorders, autoimmunological diseases, communicable diseases and cancers.

Biomedycyna Polska S. A. maintains a strong research and development division, which allows for creation of brand-new solutions in the form of applications for innovative API production processes and innovative product solutions.

BIOTECHNOLOGICAL CORPORATE GROUP

We invest into development of innovative pharmaceuticals and APIs for treatment and prevention of the main lifestyle diseases

STRUCTURE OF THE GROUP

COMPANIES BELONGING TO BIOMEDYCYNAPOLSKA S. A. GROUP

The institute’s goal is the development of new and improved technologies for separation and purification of active pharmaceutical ingredients (API), from first laboratory level stages and all the way to production scale. Research and development of proprietary medicinal products is another key field of activity. Services offered pertain to the development and optimization of processes for isolation of substances from biological materials, especially:

- Testing and analysis for food and pharmaceutical industries,
- Analysis of biological activity in vitro,
- Consulting and support of development of new and improvement of existing technologies for extraction, including membrane and chromatographic techniques,
- Performing qualitative and quantitative analyses

Pharmfactor specializes in extracting and purifying compounds from animal tissues on industrial scale, mainly peptide and protein preparations, for use as active pharmaceutical ingredients and dietary supplements. The company provides services in the fields of production and packaging of dietary supplements.

Marketing authorization holder for the original TFX drug (Thymus Factor X) – one of the five in the history of Polish pharmacy. The company specializes in development of innovative thymus preparations. Its mission is the propagation of the idea of thymotherapy among patients and doctors as well as providing them with thymus formulations of the highest quality.

COMPANY’S EQUITY CAPITAL

The equity capital of BiomedycynaPolska S. A. is 3.067.500 zł. Capital has been fully paid up. Dolnośląskie Centrum Doradztwa Gospodarczego Sp. z o.o. is the sole shareholder.